ASM Global’s SAVOR Food Division Announces U.S. Winners of World’s Premier Search Competition for Young Culinary and Hospitality Talent
24.8.2023 16:00:00 EEST | Business Wire | Press release
SAVOR, the culinary division of the world’s leading producer of live-event experiences, ASM Global, has announced Marcus Youn, chef from Knife Pleat, Regina Gutierrez, waiter from The French Laundry and Mitchell Coriell, mixologist from Soho House – Malibu the winners of the American round of the renowned World Young Chef Young Waiter (WYCYW) competition.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230823913776/en/
Judge/Chef Roland Passot (right) evaluates contestant Marcus Youn during the chef competition of Young Chef Young Waiter USA on Aug. 21, 2023, at the CIA at Copia. Youn would go on to win first place in the competition and heads to Monaco to compete in the world finals in November. (Photo: Andreas Zhou/SAVOR)
Now in its 44th year, WYCYW is the premier competition promoting hospitality as a career choice, aimed at finding the world’s most skilled chefs, waiters and waitresses under the age of 28.
All three winners from YCYW USA will go on to compete in the World Young Chef Young Waiter finals on Nov. 23 and 24 at the Lycée Rainier III in Monaco to showcase their abilities to world-class chefs, hospitality experts and mixologists. A total of 21 contestants from nine countries will face off for the chance to win the world title of best chef, waiter and mixologist under the age of 28 as well as a cash prize of $10,000.
The finals of YCYW USA took place on Aug. 21, 2023, at the prestigious The Culinary Institute of America at Copia (CIA) in Napa, California. Each of the 11 talented young hospitality stars at the finals submitted a video entry to YCYW USA, which was then whittled down by a panel of expert judges, including Roland Passot, propriétaire and chief culinary officer; Adam Busby, certified master chef and general manager of CIA in St. Helena; and more.
These industry veterans also led the in-person judging at the CIA at Copia where finalists were assessed on creativity, innovation, attention to detail and technical ability over an exciting one-day live finale. The USA winners were chosen from a pool of finalists who represented some of the country’s finest establishments, including Knife Pleat, The Surf Club, The French Laundry, Bouchon Bistro, Ad Hoc + Addendum and more.
“We are so proud to host the first-ever YCYW USA competition, as giving these young culinary stars a platform to showcase their skills has always been a priority at SAVOR,” said Shaun Beard, SAVOR’s senior vice president of food and beverage. “During the finale event, not only did we witness remarkable talent from all of the contestants, but we were amazed by their composure, camaraderie, willingness to help and genuine appreciation for each other’s crafts in a high-pressure situation. All competitors have bright and successful futures ahead of them, and we can’t wait to see what they have in store for us next.”
WYCYW aims to highlight the remarkable talent of the finest young professionals building their careers in the industry while championing the skill and passion that hospitality professionals bring to their work. For more information, please visit https://youngchefyoungwaiter.com/.
About SAVOR
SAVOR is the culinary division of ASM Global, the world's leading producer of entertainment experiences, which spans five continents and more than 350 of the world’s most prestigious arenas, stadiums, convention and exhibit centers, and performing arts venues. The team at SAVOR provides top-notch experiences at every event, from the food preparation to the beverage offerings, whether for intimate VIP experiences or banquets with over 20,000 guests. Besides great, authentic chef-driven food, the core elements of SAVOR's food vision include partnerships with local growers, producers and community members; a commitment to using antibiotic-free meats and poultry; and dedication to minimizing impact on the environment through robust sustainability, recycling and composting programs. For more information, please visit savorasmglobal.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230823913776/en/
Contact information
Carla Schalman
breakwhitelight (for ASM Global)
carla@breakwhitelight.com
310-827-3169
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 15:32:00 EEST | Press release
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company's plans to advance the program globally. The FDA granted RPD Designation based on its determination that A-T is a serious and life-threatening disease that primarily affects individ
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 15:00:00 EEST | Press release
Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT), sensor, and asset data. It helps organizations track and visualize public events, supply chains, and infrastructure to identify and respond to potential threats. ArcGIS Velocity for ArcGIS Enterprise expands cloud-native support to enterprise customers across industries in government and business that rely on firewall protection and internal security compliance. ArcGIS Velocity connects to more than 20 ready-to-use feeds for real-time data providers, including Dataminr, Samsara, Fli
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 15:00:00 EEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 15:00:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, umbilical, manifolds, multiphase flowmeters and control systems, along with installation, commissionin
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 13:00:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255 million upon the full exercise of purchase warrants. The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals. The net proceeds of this financing are expected to support Agenus’ strategic prioritization of botensilimab and balstilimab (BOT+BAL) for the neoadjuvant treatment of microsatellite-stable (MSS) colon cancer, including advancement of ROBBIN1, the Company’s planned registrational Phase 3 neoadjuvant trial in microsatellite-stable (MSS) colon cancer. High-risk Stage II and Stage III MSS colon cancer affect an estimated 38,000 patients annually in the US and more than 200,000 patients worldwide,2 representing a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom